General

Title
Melanoma: percentage of patients with melanoma having biopsy-proven or palpable nodal disease and no evidence of distant metastases who undergo a lymph node dissection (LND).

Source(s)

Measure Domain

Primary Measure Domain
Clinical Quality Measures: Process

Secondary Measure Domain
Does not apply to this measure

Brief Abstract

Description
This measure is used to assess the percentage of patients with melanoma having biopsy-proven or palpable nodal disease and no evidence of distant metastases who undergo a lymph node dissection (LND).

Rationale
There is considerable variation in the quality of cancer care delivered in the United States. This variability is also present in the diagnosis and treatment of melanoma. The management of melanoma is stage specific and has evolved considerably during the past few decades, which has possibly contributed to such variation in care.

Melanoma is the sixth-most common malignancy in the United States, and it ranks second in terms of loss of years of potential life. As the incidence of melanoma continues to increase, there is a need to assess, monitor, and standardize the care of patients with melanoma. Quality indicators may help to reduce the hospital-to-hospital discrepancy in melanoma care.
## Evidence for Rationale


## Primary Health Components

Melanoma; biopsy-proven or palpable nodal disease; distant metastases; lymph node dissection (LND)

## Denominator Description

Number of patient with melanoma having biopsy-proven or palpable nodal disease and no evidence of distant metastases

## Numerator Description

Number of patients with melanoma having biopsy-proven or palpable nodal disease and no evidence of distant metastases who undergo a lymph node dissection (LND)
Evidence Supporting the Measure

Type of Evidence Supporting the Criterion of Quality for the Measure

A formal consensus procedure, involving experts in relevant clinical, methodological, public health and organizational sciences

Additional Information Supporting Need for the Measure

Unspecified

Extent of Measure Testing

Quality indicators were identified from available literature, consensus guidelines, and melanoma experts. Thirteen experts ranked potential measures for validity on the basis of the RAND/University of California, Los Angeles Appropriateness Methodology. Adherence with individual valid indicators and a composite measure of all indicators were assessed at 1,249 Commission on Cancer hospitals by using the National Cancer Data Base (NCDB; 2004 through 2005). Of 55 proposed quality indicators, 26 measures (47%) were rated as valid.

Refer to the reference listed below for further details.

Evidence for Extent of Measure Testing


State of Use of the Measure

State of Use

Current routine use

Current Use

not defined yet

Application of the Measure in its Current Use

Measurement Setting

Ambulatory/Office-based Care
Ambulatory Procedure/Imaging Center
Hospital Inpatient
Hospital Outpatient

Professionals Involved in Delivery of Health Services
Least Aggregated Level of Services Delivery Addressed

Single Health Care Delivery or Public Health Organizations

Statement of Acceptable Minimum Sample Size

Unspecified

Target Population Age

Unspecified

Target Population Gender

Either male or female

National Strategy for Quality Improvement in Health Care

National Quality Strategy Aim

Better Care

National Quality Strategy Priority

Prevention and Treatment of Leading Causes of Mortality

Institute of Medicine (IOM) National Health Care Quality Report

Categories

IOM Care Need

Getting Better

Living with Illness

IOM Domain

Effectiveness

Data Collection for the Measure

Case Finding Period
Unspecified

Denominator Sampling Frame
Patients associated with provider

Denominator (Index) Event or Characteristic
Clinical Condition

Denominator Time Window
not defined yet

Denominator Inclusions/Exclusions

Inclusions
Number of patients with melanoma having biopsy-proven or palpable nodal disease and no evidence of distant metastases

Exclusions
None

Exclusions/Exceptions
not defined yet

Numerator Inclusions/Exclusions

Inclusions
Number of patients with melanoma having biopsy-proven or palpable nodal disease and no evidence of distant metastases who undergo a lymph node dissection (LND)

Exclusions
None

Numerator Search Strategy
Fixed time period or point in time

Data Source
Registry data

Type of Health State
Does not apply to this measure

Instruments Used and/or Associated with the Measure
Computation of the Measure

Measure Specifies Disaggregation
Does not apply to this measure

Scoring
Rate/Proportion

Interpretation of Score
Desired value is a higher score

Allowance for Patient or Population Factors
not defined yet

Standard of Comparison
not defined yet

Identifying Information

Original Title
If a patient with melanoma has biopsy-proven or palpable nodal disease and no evidence of distant metastases, then the patient must undergo a LND.

Measure Collection Name
Melanoma Quality Indicators

Submitter
Karl Y. Bilimoria, MD, MS on behalf of the American College of Surgeons' Melanoma Quality Indicator Development Expert Panel - Independent Author(s)

Developer
American College of Surgeons - Medical Specialty Society

Funding Source(s)
Composition of the Group that Developed the Measure

The Melanoma Quality Indicator Development Expert Panel included 10 surgical oncologists who had a primary clinical focus in melanoma (Charles Balch, MD; Daniel Coit, MD; Stanley Leong, MD; Kelly McMasters, MD; Donald Morton, MD; Merrick Ross, MD; Vernon Sondak, MD; Kenneth Tenabe, MD; John Thompson, MD; and Jeffrey Wayne, MD), a medical oncologist (Michael Atkins, MD), a dermatologist (Mary Martini, MD), and a dermatologist/dermatopathologist (Arthur Sober, MD).

Financial Disclosures/Other Potential Conflicts of Interest

The author(s) indicated no potential conflicts of interest.

Adaptation

This measure was not adapted from another source.

Date of Most Current Version in NQMC

2009 Nov

Measure Maintenance

Unspecified

Date of Next Anticipated Revision

Unspecified

Measure Status

This is the current release of the measure.

The measure developer reaffirmed the currency of this measure in January 2017.

Measure Availability

Source available from the Journal of Clinical Oncology.

For more information, contact Karl Bilimoria, MD, MS, Division of Research and Optimal Patient Care, American College of Surgeons, Department of Surgery, Feinberg School of Medicine, Northwestern University, 633 Clark Street, Evanston, IL 60208; Email: k-bilimoria@northwestern.edu.

NQMC Status

This NQMC summary was completed by ECRI Institute on May 18, 2012. This information was verified by the measure developer on July 11, 2012.

The information was reaffirmed by the measure developer on January 31, 2017.
Copyright Statement

This NQMC summary is based on the original measure, which is subject to the American Society of Clinical Oncology’s (ACSO’s) copyright restrictions. For permission to reuse, please contact permissions@asco.org.

Production

Source(s)


Disclaimer

NQMC Disclaimer

The National Quality Measures Clearinghouseâ¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.